Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | VHL | P40337 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SETDB1 | Q15047 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393669 | 0.71 | KMT2A (0.34) | KMT2ASETDB1TRPV1 | |
| SCHEMBL2070480 | 0.69 | NPSR1 (0.46) | NPSR1MAPTALDH1A1KDM4EHTT | |
| SCHEMBL695048 | 0.68 | — | — | |
| SCHEMBL5178524 | 0.68 | RAB9A (0.50) | NPSR1ALOX15VHLMAPTALDH1A1 | |
| SCHEMBL13167386 | 0.67 | NPSR1 (0.47) | NPSR1ALOX15VHLMAPTALDH1A1 | |
| SCHEMBL5178520 | 0.67 | NPSR1 (0.47) | NPSR1ALOX15VHLMAPTALDH1A1 | |
| SCHEMBL9298064 | 0.67 | FPR2 (0.50) | NPSR1ALOX15MAPTALDH1A1KMT2A | |
| SCHEMBL13634357 | 0.66 | L3MBTL1 (0.54) | NPSR1ALOX15MAPTALDH1A1KMT2A | |
| SCHEMBL8630597 | 0.66 | NPSR1 (0.42) | NPSR1ALOX15VHLMAPTALDH1A1 | |
| SCHEMBL7249181 | 0.66 | NPSR1 (0.50) | NPSR1ALOX15VHLMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050750-A2 | Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes | CEPHALON, INC. (US) | 2009-04-22 | — | — | EP | claimed |
| US-7122679-B2 | Multicyclic compounds and the use thereof | CEPHALON, INC. (US) | 2006-10-17 | — | — | US | claimed |
| US-8716493-B2 | Multicyclic compounds and the use thereof | CEPHALON, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2066324-B1 | CYCLOALKANOPYROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS | CEPHALON INC (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20110059959-A1 | NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF | CEPHALON, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2050750-B1 | Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes | CEPHALON INC (US) | 2010-09-22 | — | — | EP | disclosed |
| EP-2050750-A2 | Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes | CEPHALON, INC. (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1754707-A2 | Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes | CEPHALON, INC. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060276497-A1 | Novel multicyclic compounds and the use thereof | CEPHALON, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| US-7122679-B2 | Multicyclic compounds and the use thereof | CEPHALON, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1294725-B1 | MULTICYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PARP, VEGFR2 AND MLK3 ENZYMES | CEPHALON INC (US) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276497-A1 | Novel multicyclic compounds and the use thereof | MLKL, PARP3, PARP1 | NPSR1 2383/4885ALOX15 380/4885VHL 605/4885 |
| US-20110059959-A1 | NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF | MLKL, PARP3, PARP1 | NPSR1 2383/4885ALOX15 380/4885VHL 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.